SigInSpace Secures RMB 80 Million Series A Financing to Advance Global Clinical Development of 'Organoid + AI' Oncology Pipeline

Every day AI Express, January 14th, SIGNET's official WeChat account announced the completion of an 80 million RMB Series A financing round. This round was jointly invested by XtalPi, Songhe Capital, Zhisheng Synergy, Tiantu Yiyi Capital, and Blue Ocean Capital. The funds will mainly be used to advance the global Phase II clinical trial of the company’s first pipeline, SIGX1094, as well as the IND application and Phase I clinical trial for the second pipeline, SIGX2649, further expanding the company's presence in targeted therapies for malignant metastatic solid tumors. In addition to its pipelines, this round of financing will also actively promote the business expansion of the company’s organoid platform in empowering drug innovation and R&D.